Follow us for regular updates on the latest xCELLigence and NovoCyte news, events, and more. Founded in 2002, ACEA Biosciences, Inc. is a pioneer in the development and commercialization of high performance technology for cellular analysis. With headquarters in San Diego, California, ACEA also has world-class manufacturing operations in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEAÍs proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology ismarketed globally under the xCELLigence and NovoCyte brands. There are over 1,000 customers worldwide, and over 500 peer-reviewed publications using ACEA's technology. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the xCELLigence biosensor technology and proprietary small molecule library (more than 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.